Literature DB >> 23746832

In situ laser fenestration during emergent thoracic endovascular aortic repair is an effective method for left subclavian artery revascularization.

Richard E Redlinger1, Sadaf S Ahanchi, Jean M Panneton.   

Abstract

BACKGROUND: Retrograde laser fenestration of the left subclavian artery (LSA) during emergent thoracic endovascular aortic repair (TEVAR) uses a relatively simple intraoperative method of endograft modification to revascularize aortic branches for a variety of acute thoracic aortic pathologies. This study presents our expanded experience and midterm outcomes of TEVAR with laser fenestration to revascularize the LSA as an alternative to debranching.
METHODS: Patients who underwent TEVAR with LSA revascularization by laser graft fenestration from September 2009 through August 2012 were retrospectively reviewed. TEVAR was performed with deployment of a Dacron (DuPont, Wilmington, Del) endograft over the LSA orifice. Laser catheter fenestration of the graft was performed through retrograde brachial access, followed by balloon-expandable covered stent deployment through the fenestration to traverse the endograft and LSA. Routine postoperative follow-up imaging with computed tomography angiography was performed to assess TEVAR and LSA fenestration patency, endoleak, and aneurysm/dissection exclusion.
RESULTS: TEVAR with laser fenestration was successfully performed in 22 patients (12 men; mean age, 57 years) in an urgent or emergent setting secondary to unremitting symptoms or rupture. Twelve patients had large symptomatic thoracic aortic aneurysms (eight secondary to chronic dissection); four patients had acute symptomatic type B aortic dissection, and six patients had an intramural hematoma or penetrating aortic ulcer, or both. An average of two endografts (range, 1-4) were deployed. LSA-covered stents were 8 to 10 mm in diameter. Mean operative time was 154 ± 65 minutes. Average hospital length of stay was 12 ± 7 days. No major fenestration-related complications occurred. One patient developed postoperative paraplegia. One patient died in the postoperative period, for an in-hospital mortality rate of 4.5%. Two patients died of non-TEVAR-related causes at a mean follow-up of 10 months (range, 1-40 months). Follow-up computed tomography angiography imaging demonstrated a 100% primary patency for the LSA stents. One patient had an asymptomatic LSA stent stenosis. Type II endoleaks from the LSA in two patients required endovascular coil embolization. No fenestration-related type I or III endoleaks were noted.
CONCLUSIONS: In situ retrograde laser fenestration is a feasible and effective option for LSA revascularization during TEVAR involving a spectrum of acute thoracic aortic pathology. Laser fenestration provides a rapid, reproducible method of fenestrating the endograft material. The high technical success, low fenestration-related morbidity, and excellent midterm patency support this technique of intraoperative endograft modification.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746832     DOI: 10.1016/j.jvs.2013.04.045

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  24 in total

1.  Outcomes of thoracic endovascular aortic repair using aortic arch chimney stents in high-risk patients.

Authors:  Igor Voskresensky; Salvatore T Scali; Robert J Feezor; Javairiah Fatima; Kristina A Giles; Rosamaria Tricarico; Scott A Berceli; Adam W Beck
Journal:  J Vasc Surg       Date:  2017-07       Impact factor: 4.268

2.  Preservation of Internal Iliac Artery after Endovascular Repair of Common Iliac Artery Dissection Using Modified Fenestrated Stent Graft.

Authors:  Binshan Zha; Huagang Zhu; Bin Liu; Yusheng Ye; Jun Li
Journal:  Korean Circ J       Date:  2016-04-28       Impact factor: 3.243

3.  Endovascular total arch replacement techniques and early results.

Authors:  Vladimir Makaloski; Nikolaos Tsilimparis; Fiona Rohlffs; Franziska Heidemann; Eike Sebastian Debus; Tilo Kölbel
Journal:  Ann Cardiothorac Surg       Date:  2018-05

4.  Aortic Dissection: Novel Surgical Hybrid Procedures.

Authors:  Alessandro Cannavale; Mariangela Santoni; Fabrizio Fanelli; Gerard O'Sullivan
Journal:  Interv Cardiol       Date:  2017-05

5.  Thoracic Endovascular Aortic Repair With Left Subclavian Artery Coverage Is Associated With a High 30-Day Stroke Incidence With or Without Concomitant Revascularization.

Authors:  Rens R B Varkevisser; Nicholas J Swerdlow; Livia E V M de Guerre; Kirsten Dansey; Chun Li; Patric Liang; Christopher A Latz; Mathijs T Carvalho Mota; Hence J M Verhagen; Marc L Schermerhorn
Journal:  J Endovasc Ther       Date:  2020-05-21       Impact factor: 3.487

6.  Percutaneous In situ Left Subclavian Artery Fenestration Using Reentry Catheter during Endovascular Thoracic Aortic Aneurysm Repair.

Authors:  Tze-Woei Tan; Amy H Coulter; Wayne W Zhang
Journal:  Int J Angiol       Date:  2015-01-12

Review 7.  Endovascular Treatment of Various Aortic Pathologies: Review of the Latest Data and Technologies.

Authors:  Koji Maeda; Takao Ohki; Yuji Kanaoka
Journal:  Int J Angiol       Date:  2018-05-07

Review 8.  Spinal cord injury after thoracic endovascular aortic aneurysm repair.

Authors:  Hamdy Awad; Mohamed Ehab Ramadan; Hosam F El Sayed; Daniel A Tolpin; Esmerina Tili; Charles D Collard
Journal:  Can J Anaesth       Date:  2017-10-10       Impact factor: 5.063

Review 9.  Revascularisation of the left subclavian artery for thoracic endovascular aortic repair.

Authors:  Shahin Hajibandeh; Shahab Hajibandeh; Stavros A Antoniou; Francesco Torella; George A Antoniou
Journal:  Cochrane Database Syst Rev       Date:  2016-04-27

10.  Outcomes of single physician-modified fenestrated stent grafts for endovascular repair of thoracic aortic lesions involving the distal aortic arch.

Authors:  Jiechang Zhu; Chao Ma; Xiangchen Dai; Zheng Wang; Hailun Fan; Zhou Feng; Yudong Luo; Yiwei Zhang; Fanguo Hu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.